FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Instruction 1(b).			Filed pursuant to Section 16(a) of the Securities Exchange Act of 193-	4	Indus per i	esponse. 0.0			
			or Section 30(h) of the Investment Company Act of 1940						
1. Name and Add Aftab Blak	dress of Reporting	Person*	2. Issuer Name <b>and</b> Ticker or Trading Symbol Adicet Bio, Inc. [ ACET ]		ionship of Reporting Pe all applicable)	Reporting Person(s) to Issuer ole)			
——————————————————————————————————————	<u> </u>			$\perp$ x	Officer (give title	10% Owner Other (specify			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	"	below)	below)			
C/O ADICET	BIO, INC.		10/12/2021		Chief Scientifi	f Scientific Officer			
200 CLARENDON STREET		Γ							
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable					
(Street)				Line)	Form filed by One Re	porting Person			
BOSTON	MA	02116			Form filed by More than One Reporting				
(0:1-)	(0+-+-)	(7:)			Person				
(City)	(State)	(Zip)							
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									

#### 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 3. Transaction 5. Amount of 6. Ownership 7. Nature Form: Direct (D) or Indirect of Indirect Beneficial Execution Date, (Month/Day/Year) Beneficially if any (Month/Day/Year) 5) Code (Instr. 8) Owned Following (I) (Instr. 4) Ownership Reported (Instr. 4) (A) or (D) Transaction(s) (Instr. 3 and 4) ٧ Price Code Amount 80,000(1) Common Stock 10/12/2021 Α \$0.00 80,000 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

# (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of Expiration Date (Month/Day/Year) Securities Acquired (A) or Disposed		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	of (D) (I 3, 4 and		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (right to Buy)	\$7.38	10/12/2021		A		60,000		(2)	10/11/2031	Common Stock	60,000	\$0.00	60,000	D	

### **Explanation of Responses:**

1. The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 12, 2022 and the second tranche vesting on October 12, 2023. The remaining shares shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

# Remarks:

/s/ Nick Harvey, Attorney-in-

**Fact** 

10/13/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>2. 25%</sup> of the shares subject to the stock option shall vest on October 12, 2022, and the remainder of the shares shall vest in equal monthly installments for a period of 36 months thereafter, subject to continued service with the Company.